MyChem

Executive Summary

MyChem LLC is a San Diego-based private company founded in 2015, specializing in the synthetic production of ultra-pure nucleotides for next-generation sequencing (NGS) and other applications. Their nucleotides—natural, modified, and dye-labeled—are manufactured synthetically, ensuring freedom from cross-base contamination and enzyme activities that can compromise sequencing accuracy. This purity is critical for NGS, where even trace impurities can lead to errors, positioning MyChem as a key supplier to sequencing platforms and research institutions. As the NGS market expands, driven by genomics, diagnostics, and personalized medicine, MyChem’s high-quality, consistent products offer a defensible niche in the value chain. Despite limited public financial information, MyChem’s synthetic approach provides scalability and quality advantages over competitors using biological extraction. The company is well-positioned to capture growth as demand for ultra-pure nucleotides rises. Upcoming catalysts may include strategic partnerships with major sequencing players, expansion into modified nucleotides for RNA therapeutics, or a funding round to scale operations. MyChem’s focus on a critical, high-purity input for NGS suggests a solid foundation for future value creation, though near-term visibility remains moderate.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major NGS platform company40% success
• Q3 2026Launch of new nucleotide products for RNA-based therapeutics30% success
• Q4 2026Series A or B funding round to expand manufacturing capacity50% success